E2E Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 10-01-2025
- Paid Up Capital ₹ 0.10 M
as on 10-01-2025
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 26.67%
(FY 2022)
- Profit 101.34%
(FY 2022)
- Ebitda 110.56%
(FY 2022)
- Net Worth 0.22%
(FY 2022)
- Total Assets -24.83%
(FY 2022)
About E2E Biotech
The Company is engaged in the Professional Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dayananda Chandrappa, Gururaj Harishchandra, Gudadappa Chandrappa, and One other member serve as directors at the Company.
- CIN/LLPIN
U74999KA2016PTC095022
- Company No.
095022
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at E2E Biotech?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dayananda Chandrappa  | Director | 15-Jul-2016 | Current |
| Gururaj Harishchandra | Director | 15-Jul-2016 | Current |
| Gudadappa Chandrappa | Additional Director | 06-Apr-2022 | Current |
| Harishchandra Bharathi | Additional Director | 06-Apr-2022 | Current |
Financial Performance of E2E Biotech.
E2E Biotech Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 26.67% increase. The company also saw a substantial improvement in profitability, with a 101.34% increase in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of E2E Biotech?
In 2017, E2E Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Karmayogi Foods Private LimitedActive 7 years 2 monthsDayananda Chandrappa and Gururaj Harishchandra are mutual person
- Syrimed Lifesciences Private LimitedActive 2 years 8 months
Dayananda Chandrappa and Gudadappa Chandrappa are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at E2E Biotech?
Unlock and access historical data on people associated with E2E Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of E2E Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped E2E Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
